Nrf2 Inhibition May Exacerbate Inflammation through Il-6 and Increased Oxidative Stress In Chronic Fatigue Syndrome and Fibromyalgia




In past entries I've argued that NRF2, or lack thereof, is an important factor in CFS and possibly other environmental illnesses. Further, I explained how circadian rhythms can be disturbed in CFS, and NRF2 is closely linked to how “efficient” the circadian clocks work. For instance, it has been demonstrated that the production of NRF2 works on a “clock” schedule. Specifically, peak production occurs at around 2:00 AM and production of the least amount occur at around 8:00 PM at night. Coincidentally, the immune system and its production of inflammatory cytokines is most active at night during sleep. In addition, a recent study by Eccles found that the pain and fatigue in CFS and fibromyalgia is driven by the level of interleukin 6 upon challenge, a cytokine that is mostly known as an inflammatory marker. 

NRF2 can respond to both viral and bacterial infections and as you will see, in two important ways. So, what does this have to do with CFS and fibromyalgia? You might have heard that many patients claim their CFS started after a virus and in my case, this is true.  It has It has been known for a long time that NRF2 is important regulator of redox control within cells. Oxidative stress has been implicated in CFS, fibro and other environmental diseases and contributes to the pathology of neurodegenerative disease. Generally, oxidative stress is a waste product of cellular processes and when allowed to accumulate, can cause tissue damage. It is also produced by the mechanics of energy production in mitochondria, which are the energy producers of all cells, and produced from inflammatory cells in large amounts. “Environmental illnesses” are now considered to be at least in part, oxidative-stress driven and NRF2 plays an important role in producing antioxidants that neutralize oxidative stress by stimulating the activation of their genes. 

Around the year 2016 an important discovery was made in that NRF 2 has the capability to repress the activation of genes that encode for interleukin 6 and interleukin-1 beta. IL-6 is inflammatory and along with IL-1b play an important part in the inflammatory process of cells. This repressive role of NRF2 is opposite to the one that NRF2 plays in the activation of antioxidant genes. The exact nature of how an NRF2 acts on the genes of interleukin 6 and interleukin -1b is not completely known, but from what we do know, NRF2 binds to the DNA near the genes of the cytokines to repress their production. Realistically, it is not too far of a stretch to say that NRF2 may play a part in the repression of inflammatory mediators like interleukin 6 in chronic fatigue syndrome and fibromyalgia and even other “environmental illnesses”. The fact that NRF2 repression has an impact on other viral and bacterial diseases provides circumstantial evidence that it could neutralize inflammation in “somatic syndromes”. Through different studies it has been demonstrated the activation of NRF2 inhibits Zika, Ebola and influenza A. (Harengt) Not only that, but activation of NRF2 in animal studies has led to reduced mortality and a longer life after infection. This shows that NRF 2 has benefits over a large range of viruses. In situations where NRF2 is reduced, like with RSV the virus and where there is degradation of NRF2, there are lower levels of antioxidants and worse outcomes. In COVID, suppression of NRF2 leads to worse pathogenesis and more severe disease. In pediatric patients, NRF2 suppression led to increasing oxidative stress. (gumus) Also, it has been shown that NRF2 levels are lower in covid-symptomatic patients than in covid-asymptomatic patients. And this observation may eventually lead to a clinical biomarker of disease severity. (Mihic)  The author does state that it is “not known whether a reduction in NRF 2 is caused by COVID or if NRF2 reduction makes a person more susceptible to COVID. What has been found is that age, dysbiosis, obesity, high blood sugar, and male gender are all risk factors for NRF2 reduction. Coincidentally, they are also risk factors for severe COVID.”

Endotoxemia from LPS bacterial infection has been implicated in CFS because of bacteria crossing the lining of the intestine, activating Toll receptors, and causing systemic inflammation. It has been shown that NRF2 suppresses interleukin -6 and interleukin -1 in macrophages. (Kobayashi)Models show NRF2 interferes with the interleukin induction inflammatory phenotypes and LPS stimulated macrophages. I will remind you here gut inflammation from dysbiosis of the microbiome leads to pro-inflammatory environment. Macrophages then cause more inflammation and increases translocation of LPS which increases reactive oxygen and nitrogen species and therefore, produces oxidative stress to cause “leaky gut.”  Systemic LPS infection can enter the CNS via the blood brain barrier and interact with the microglia, which can adversely affect neurogenesis, cognition, and memory. All of which are symptoms of chronic fatigue syndrome, fibromyalgia, and other somatic syndromes.

In other studies, NRF2 deficiency caused inflammation exacerbation in sepsis, pleurisy, emphysema and autoimmune diseases in rodents. In an experimental model of infection, mice were exposed to Staphylococcus aureus, the NRF2- knockout mice showed an increased level of inflammation response compared to wild-type mice.  This study supports the theory that NRF2 inhibits interleukin-6 in vivo in mice.(Kobayashi)

All these findings support the theory that NRF2 is an important redox and inflammatory regulator. Since pain and fatigue are believed to be dependent on the production of interleukin 6 in chronic fatigue syndrome and fibromyalgia, it can be assumed that NRF2 might play a role in the inflammatory responses in these syndromes. As I have pointed out here and elsewhere, there are many factors that inhibit the production of NRF2, including high-fat and high sugar diets, chemical inhibitors, poor sleep, aging, obesity, etcetera. Many of these factors are preventable through lifestyle changes. And if we make them, we may be able to control these “somatic syndromes” and live a better quality of live until a “cure” can be found.

Read more:
Follow us - Twitter/X    Join the Facebook Group    Facebook




Wang Y, Ma J, Jiang Y. Transcription factor Nrf2 as a potential therapeutic target for COVID-19. Cell Stress Chaperones. 2023 Jan;28(1):11-20. doi: 10.1007/s12192-022-01296-8. Epub 2022 Nov 22. PMID: 36417098; PMCID: PMC9685020.

Morris G, Maes M, Berk M, Puri BK. Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop? Metab Brain Dis. 2019 Apr;34(2):385-415. doi: 10.1007/s11011-019-0388-6. Epub 2019 Feb 13. PMID: 30758706; PMCID: PMC6428797.

Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Hayashi M, Sekine H, Tanaka N, Moriguchi T, Motohashi H, Nakayama K, Yamamoto M. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun. 2016 May 23;7:11624. doi: 10.1038/ncomms11624. PMID: 27211851; PMCID: PMC4879264.

Qu Y, Haas de Mello A, Morris DR, Jones-Hall YL, Ivanciuc T, Sattler RA, Paessler S, Menachery VD, Garofalo RP, Casola A. SARS-CoV-2 Inhibits NRF2-Mediated Antioxidant Responses in Airway Epithelial Cells and in the Lung of a Murine Model of Infection. Microbiol Spectr. 2023 Jun 15;11(3):e0037823. doi: 10.1128/spectrum.00378-23. Epub 2023 Apr 6. PMID: 37022178; PMCID: PMC10269779.

Lonsdale DO, Shah RV, Lipman J. Infection, Sepsis and the Inflammatory Response: Mechanisms and Therapy. Front Med (Lausanne). 2020 Dec 2;7:588863. doi: 10.3389/fmed.2020.588863. PMID: 33344475; PMCID: PMC7738462.

Eccles JA, Thompson B, Themelis K, Amato ML, Stocks R, Pound A, Jones AM, Cipinova Z, Shah-Goodwin L, Timeyin J, Thompson CR, Batty T, Harrison NA, Critchley HD, Davies KA. Beyond bones: The relevance of variants of connective tissue (hypermobility) to fibromyalgia, ME/CFS and controversies surrounding diagnostic classification: an observational study. Clin Med (Lond). 2021 Jan;21(1):53-58. doi: 10.7861/clinmed.2020-0743. PMID: 33479068; PMCID: PMC7850199.

OPO194 Inflammation-Induced Pain and Fatigue in Fibromyalgia and ME/CFS and the Role of Variant Connective Tissue. Jessica Eccles, Marisa Amato, Kristy Themelis, and Lisa Quadt. Annals of Rheumatic Diseases. May 2023. 82(Suppl 1): 129.2-129

He F, Ru X, Wen T. NRF2, a Transcription Factor for Stress Response and Beyond. Int J Mol Sci. 2020 Jul 6;21(13):4777. doi: 10.3390/ijms21134777. PMID: 32640524; PMCID: PMC7369905.

Saha S, Buttari B, Panieri E, Profumo E, Saso L. An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation. Molecules. 2020 Nov 23;25(22):5474. doi: 10.3390/molecules25225474. PMID: 33238435; PMCID: PMC7700122.

Robledinos-Antón N, Fernández-Ginés R, Manda G, Cuadrado A. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid Med Cell Longev. 2019 Jul 14;2019:9372182. doi: 10.1155/2019/9372182. PMID: 31396308; PMCID: PMC6664516.

Herengt A, Thyrsted J, Holm CK. NRF2 in Viral Infection. Antioxidants (Basel). 2021 Sep 18;10(9):1491. doi: 10.3390/antiox10091491. PMID: 34573123; PMCID: PMC8472116.

Gümüş H, Erat T, Öztürk İ, Demir A, Koyuncu I. Oxidative stress and decreased Nrf2 level in pediatric patients with COVID-19. J Med Virol. 2022 May;94(5):2259-2264. doi: 10.1002/jmv.27640. Epub 2022 Feb 16. PMID: 35128704; PMCID: PMC9088523.

Muchtaridi M, Amirah SR, Harmonis JA, Ikram EHK. Role of Nuclear Factor Erythroid 2 (Nrf2) in the Recovery of Long COVID-19 Using Natural Antioxidants: A Systematic Review. Antioxidants (Basel). 2022 Aug 10;11(8):1551. doi: 10.3390/antiox11081551. PMID: 36009268; PMCID: PMC9405009.

Mihić D, Loinjak D, Maričić L, Smolić R, Šahinović I, Steiner K, Viland S, Šerić V, Duvnjak M. The Relationship between Nrf2 and HO-1 with the Severity of COVID-19 Disease. Medicina (Kaunas). 2022 Nov 16;58(11):1658. doi: 10.3390/medicina58111658. PMID: 36422196; PMCID: PMC9693233.

Comments